Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A1 | P22736 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.51 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.51 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.50 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.50 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.50 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.50 |
| ▸ | ALB | P02768 | 1/20 | 0.50 |
| ▸ | ESR1 | P03372 | 1/20 | 0.50 |
| ▸ | RARB | P10826 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.50 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5216090 | 1.00 | NR4A1 (0.51) | NR4A1NR4A2NR4A3TBXAS1PTGS1 | |
| SCHEMBL5216074 | 1.00 | NR4A1 (0.51) | NR4A1NR4A2NR4A3TBXAS1PTGS1 | |
| Hydrochloric Acid SCHEMBL6784379 | 0.98 | TBXAS1 (0.52) | NR4A1NR4A2NR4A3TBXAS1PTGS1 | |
| SCHEMBL25146544 | 0.95 | TBXAS1 (0.48) | NR4A1NR4A2NR4A3TBXAS1PTGS1 | |
| SCHEMBL11485127 | 0.88 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL11805071 | 0.88 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL11485125 | 0.88 | PTGS1 (0.47) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL6784373 | 0.85 | FAAH (0.45) | PTGS1PTGS2LMNACYP2C9AKR1C3 | |
| SCHEMBL10486236 | 0.84 | TBXAS1 (0.44) | NR4A1NR4A2NR4A3TBXAS1PTGS1 | |
| SCHEMBL10486258 | 0.82 | TBXAS1 (0.43) | NR4A1NR4A2NR4A3TBXAS1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474419-B1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK AS (DK) | 2007-09-05 | — | — | EP | disclosed |
| US-7101898-B2 | For therapy of allergic rhinitis, ulcer or anorexia, diabetes, Alzheimer's disease, narcolepsy or attention deficit disorder | NOVO NORDISK A/S (DK) | 2006-09-05 | — | — | US | disclosed |
| EP-1474419-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HIGH POINT PHARMACEUTICALS, LLC | 2003-10-16 | — | — | US | disclosed |
| WO-2003064411-A1 | AMIDES OF AMINOALKYL-SUBSTITUTED AZETIDINES, PYRROLIDINES, PIPERIDINES AND AZEPANES | NOVO NORDISK A/S (DK) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195190-A1 | Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes | HRH3, HRH2, HRH4 | NR4A1 753/4885NR4A2 680/4885NR4A3 711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.